Kuter, Irene <br/><br/>
Dose-dependent change in biomarkers during neoadjuvant  endocrine therapy with fulvestrant: results from NEWEST,  a randomized Phase II study.  [electronic resource] 

 -  Breast cancer research and treatment  May 2012 
 - 237-46 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-011-1947-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Hormonal--adverse effects<br/>Biomarkers, Tumor--metabolism<br/>Breast Neoplasms--drug therapy<br/>Dose-Response Relationship, Drug<br/>Estradiol--adverse effects<br/>Female<br/>Fulvestrant<br/>Humans<br/>Ki-67 Antigen--metabolism<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasms, Hormone-Dependent--drug therapy<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Treatment Outcome